How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

63,510 results for

Type 1 Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study. Full Text available with Trip Pro

Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study. To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL-1501D and reference insulin glargine (Lantus®; Sanofi-Aventis US LLC, Bridgewater, New Jersey).Eligible participants from INSTRIDE 1 who completed 52 weeks of reference insulin glargine treatment were randomized 1:1 (...) -1501D and reference insulin glargine demonstrated equivalent efficacy and similar safety and immunogenicity, showing that people taking reference insulin glargine can safely switch to MYL-1501D.© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2020 obesity & metabolism

82. Incidence of Type 1 diabetes mellitus and effect on mortality in young patients with congenital heart defect - A nationwide cohort study. Full Text available with Trip Pro

Incidence of Type 1 diabetes mellitus and effect on mortality in young patients with congenital heart defect - A nationwide cohort study. 1% of all live born children are born with a congenital heart defect (CHD) and currently 95% reach adulthood. Type 1 diabetes mellitus (T1DM) is an autoimmune disease that can develop due to i.e. heredity, exposure to infections and stress-strain. The incidence of T1DM in patients with CHD is unknown and we analysed the risk of developing T1DM for patients

2020 International journal of cardiology

83. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Full Text available with Trip Pro

Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. To assess the cost-effectiveness of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, as an adjunct to insulin in adults with type 1 diabetes mellitus (T1DM) inadequately controlled by insulin alone in the UK setting.A cost-utility analysis was conducted to compare dapagliflozin (5 mg or 10 mg) added to insulin versus insulin monotherapy (standard (...) of care) over a lifetime horizon. Treatment efficacy and safety data were obtained from 52-week results of the DEPICT-1 and DEPICT-2 trials and a network meta-analysis of SGLT2 inhibitors in T1DM. Direct healthcare costs, life-years, and quality-adjusted life-years (QALYs) were estimated from a UK payer perspective and discounted at 3.5% annually, using the Cardiff T1DM Model. Sensitivity analyses assessed uncertainty in estimated incremental cost-effectiveness ratios (ICERs).Dapagliflozin 5 mg

2020 obesity & metabolism

84. Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus. Full Text available with Trip Pro

Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus. To report phase 1 bioequivalence results comparing MYL-1501D, US reference insulin glargine (US IG), and European reference insulin glargine (EU IG).The double-blind, randomized, three-way crossover study compared the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of MYL-1501D, US IG and EU IG. In total (...) , 114 patients with type 1 diabetes (T1DM) received 0.4 U/kg of each study treatment under automated euglycaemic clamp conditions. Insulin metabolite M1 concentrations, insulin glargine (IG) and glucose infusion rates (GIRs) were assessed over 30 hours. Primary PK endpoints were area under the serum IG concentration-time curve from 0 to 30 hours (AUCins.0-30h ) and maximum serum IG concentration (Cins.max ). Primary PD endpoints were area under the GIR-time curve from 0 to 30 hours (AUCGIR0-30h

2020 obesity & metabolism

85. Semaglutide (Ozempic) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

English part of National Health Care Institute Search Semaglutide (Ozempic®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise Zorginstituut Nederland carried out a marginal assessment of whether semaglutide (Ozempic®) is interchangeable with a drug currently included in the Medicine Reimbursement System (GVS). Registration Semaglutide belongs to the pharmacotherapeutic group of GLP-1 (glucagon-like peptide 1) receptor agonists (...) Semaglutide (Ozempic) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise Semaglutide (Ozempic®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise | Report | National Health Care Institute You are here: Semaglutide (Ozempic®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise Search within

2018 National Health Care Institute (Zorginstituut Nederland)

86. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians Full Text available with Trip Pro

conditions, or long-standing DM [diabetes mellitus] in which the A1C goal has been difficult to attain despite intensive efforts, so long as the patient remains free of polydipsia, polyuria, polyphagia, and other hyperglycemia-associated symptoms (Grade A; BEL 1). ( ) Comments According to the AACE/ACE grading scheme, “Grade A; BEL 1” indicates highest-quality evidence with little or no effect from subjective factors on recommendation (evidence mapped to recommendation) and “Grade D; BEL 4” indicates (...) Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians ACP Guidance Statement on HbA | Annals of Internal Medicine | American College of Physicians '); } Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register and create your Annals account INSTITUTIONAL SIGN IN | | Subscribe to Annals

2018 American College of Physicians

87. Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus

Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus '); } else { document.write(' '); } ACE | Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus Search > > Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus - Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus First published on 3 May 2017 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended (...) : Dapagliflozin 5 mg and 10 mg tablets, and empagliflozin 10 mg and 25 mg tablets for managing type 2 diabetes mellitus, in the following circumstances: as a dual therapy in combination with metformin for patients with HbA1c measurement greater than 7% despite treatment with metformin monotherapy and when sulfonylureas are contraindicated or not tolerated, or the person is at significant risk of hypoglycaemia or its consequences; or as a dual therapy in combination with a sulfonylurea for patients with HbA1c

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

88. Type 1 diabetes

Type 1 diabetes Type 1 diabetes - Symptoms, diagnosis and treatment | BMJ Best Practice   Search  Type 1 diabetes Last reviewed: February 2019 Last updated: March 2018 Summary Type 1 diabetes mellitus is a metabolic disorder characterised by hyperglycaemia due to absolute insulin deficiency. Patients most often present with a few days or weeks of polyuria, polydipsia, weight loss, and weakness. Some patients may present with diabetic ketoacidosis. Intensive glycaemic control has been shown (...) to decrease the incidence of microvascular and macrovascular complications. Microvascular complications include retinopathy, nephropathy, and neuropathy. Macrovascular complications include coronary artery, cerebrovascular, and peripheral vascular disease. Definition Type 1 diabetes mellitus is a metabolic disorder characterised by hyperglycaemia due to absolute insulin deficiency. The condition develops due to destruction of pancreatic beta cells, mostly by immune-mediated mechanisms. In some patients

2018 BMJ Best Practice

89. Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus

Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Type 1 diabetes happens when the cells that make insulin in the pancreas, the islets, are destroyed. Islet cell transplantation involves extracting islet cells from the pancreas

2016 Health Technology Assessment (HTA) Database.

90. Patient perspectives on quality of life with cncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis

Patient perspectives on quality of life with cncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis Patient perspectives on quality of life with controlled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis Patient perspectives on quality of life with controlled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis Vanstone M, Rewegan A, Brundisini F, Dejean D, Giacomini M Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vanstone M, Rewegan A, Brundisini F, Dejean D, Giacomini M. Patient perspectives on quality of life with controlled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series. 2015 Authors' conclusions Serious consequences of type 1

2016 Health Technology Assessment (HTA) Database.

91. Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review

Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Health Quality Ontario. Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 15(16). 2015 Authors' conclusions Islet transplantation offers an alternative for patients with type 1 diabetes who have brittle diabetes with difficult-to-control blood glucose levels or hypoglycemic unawareness despite optimal insulin therapy. Treatment

2016 Health Technology Assessment (HTA) Database.

92. Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation

Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Health Quality Ontario. Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). OHTAC Recommendation. 2015 Authors' conclusions OHTAC members acknowledged that there was uncertainty in the evidence that islet transplantation improved secondary complications of diabetes and quality of life. However, OHTAC also recognized that patients being treated with islet transplantation had a very complicated form

2016 Health Technology Assessment (HTA) Database.

93. Statement on prescribing Freestyle Libre flash glucose monitoring system for type 1 and type 2 diabetes

requiring multiple daily insulin dosing for Type 1 and Type 2 diabetes mellitus. The current evidence, however, does not support routine adoption. The use of Freestyle Libre may be considered as an alternative to finger-prick selfmonitoring of blood glucose in clinical circumstances where multiple testing (eight or more times per day) is required. Why was this topic appraised? HTW previously facilitated publication of an Interim Statement on the prescribing of FreeStyle Libre flash glucose monitoring (...) Statement on prescribing Freestyle Libre flash glucose monitoring system for type 1 and type 2 diabetes FreeStyle Libre flash glucose monitoring - Health Technology Wales > FreeStyle Libre flash glucose monitoring FreeStyle Libre flash glucose monitoring Topic Status Incomplete FreeStyle Libre flash glucose monitoring for the management of type 1 or type 2 diabetes. Outcome of the appraisal Freestyle Libre shows promise for detecting and guiding the correction of hypoglycaemia in patients

2018 Health Technology Wales

94. Zinc, copper, and oxysterol levels in patients with type 1 and type 2 diabetes mellitus. (Abstract)

Zinc, copper, and oxysterol levels in patients with type 1 and type 2 diabetes mellitus. The present study has the objective to assess the zinc (Zn), copper (Cu), and oxysterols plasma levels in type 1 (DM1) (n = 26) and type 2 (DM2) (n = 80) diabetes patients, as compared to healthy controls (n = 71), in order to testify whether metal levels may have a significant impact on the association between oxysterols and diabetes.Plasma trace elements and plasma oxysterols were assessed using atomic (...) levels were reported. The 7-ketocholesterol (7-kchol) levels in DM1 and DM2 patients exceeded these values in healthy individuals by 2.5 and 5-fold, respectively. Similarly, cholestan-3β, 5α, 6β-triol (chol-triol) levels were more than 3- and 6-fold higher when compared to the respective values in non-diabetic controls. In regression models decreased plasma Zn and elevated oxysterol levels were significantly associated with HbA1c and fasting plasma glucose levels, after adjustment for anthropometric

2019 Clinical nutrition (Edinburgh, Scotland)

95. Correction to: Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Full Text available with Trip Pro

Correction to: Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE In the Original publication of the article, the legend appearing inside the flow chart has been incorrectly published.

2019 Heart and vessels Controlled trial quality: uncertain

96. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria. Full Text available with Trip Pro

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria. This analysis evaluates the cost-effectiveness of insulin degludec (degludec) versus biosimilar insulin glargine U100 (glargine U100) in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in Bulgaria.A simple, short-term model was used to compare the treatment costs and outcomes associated with hypoglycaemic events with degludec versus glargine U100 (...) in patients with T1DM and T2DM from the perspective of the Bulgarian National Health Insurance Fund. Cost-effectiveness was analysed over a 1-year time horizon using data from clinical trials. The incremental cost-effectiveness ratio (ICER) was the main outcome measure.In Bulgaria, degludec was highly cost-effective versus glargine U100 in people with T1DM and T2DM. The ICERs were estimated to be 4493.68 BGN/quality-adjusted life year (QALY) in T1DM, 399.11 BGN/QALY in T2DM on basal oral therapy (T2DMBOT

2019 BMC Endocrine Disorders

97. Maternal Gestational Diabetes Mellitus, Type 1 Diabetes, and Type 2 Diabetes During Pregnancy and Risk of ADHD in Offspring. Full Text available with Trip Pro

Maternal Gestational Diabetes Mellitus, Type 1 Diabetes, and Type 2 Diabetes During Pregnancy and Risk of ADHD in Offspring. To examine the relative importance of maternal preexisting type 1 diabetes (T1D), preexisting type 2 diabetes (T2D), and gestational diabetes mellitus (GDM) on risk of attention deficit/hyperactivity disorder (ADHD) in offspring.This retrospective birth cohort study included 333,182 singletons born in 1995-2012 within Kaiser Permanente Southern California hospitals (...) . Children were prospectively followed through electronic medical records from age 4 years. Relative risks of ADHD associated with diabetes exposures in utero were estimated by hazard ratios (HRs) using Cox regression with adjustment for potential confounders. For GDM, timing of exposure was evaluated by gestational age at diagnosis and severity was assessed by the need for antidiabetes medication treatment during pregnancy.A total of 37,878 (11.4%) children were exposed to diabetes (522 exposed to T1D

2018 Diabetes Care

98. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus. Full Text available with Trip Pro

Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus. To evaluate the evidence for the novel dual sodium-glucose co-transporter-1 (SGLT1) and -2 (SGLT2) inhibitor, sotagliflozin, which may enhance the efficacy of SGLT2 inhibitors by additionally reducing intestinal glucose absorption.The search terms 'sotagliflozin', 'LX4211', 'SGLT' and 'diabetes' were entered into PubMed. Evidence for the pharmacokinetics (...) , pharmacodynamics, safety and efficacy of sotagliflozin in Type 1 and 2 diabetes was extracted from the retrieved literature, critically evaluated, and contextualized in relation to data on existing SGLT2 inhibitors.There is convincing evidence from a range of phase II and III clinical trials that sotagliflozin significantly improves glycaemic control in both Type 1 and Type 2 diabetes. Additional benefits, such as smaller postprandial plasma glucose excursions, lower insulin requirements, appetite suppression

2018 Diabetic Medicine

99. Insulin degludec (Type 1 diabetes mellitus) ? Benefit assessment according to §35a Social Code Book V

Insulin degludec (Type 1 diabetes mellitus) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Assessment module I, Sections I 2.1 to I 2.6, and Assessment module II, Sections II 2.1 to II 2.6, of the dossier assessment Insulin degludec – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) Commissioning agency: Federal Joint Committee Commission awarded on: 29 April 2014 Internal Commission No.: A14-13 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A14-13 – Benefit assessment acc. to §35a SGB V Version 1.0 Insulin degludec – Type 1 diabetes mellitus 30 July 2014 Institute for Quality

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

100. Excess mortality and life expectancy of individuals with type 1 diabetes: a rapid review

: Diabetes Mellitus, Type 1; Life expectancy; Mortality; Survival NLM Classification: WK810 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2019/10.273/37 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-publications. How to refer to this document? Louwagie P, De Laet C, Roberfroid D. Excess mortality and life expectancy of individuals with type 1 diabetes: a rapid review. Health Services (...) Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). 2019. KCE Reports 314. D/2019/10.273/37. This document is available on the website of the Belgian Health Care Knowledge Centre. KCE Report 314 Excess mortality and life expectancy of individuals with type 1 diabetes 1 ? TABLE OF CONTENTS LIST OF TABLES 4 LIST OF ABBREVIATIONS 5 ? SCIENTIFIC REPORT 7 1 BACKGROUND 7 1.1. CONTEXT 7 1.2. RESEARCH QUESTION 7 1.3. TYPE 1 DIABETES MELLITUS 7 1.4. GENERAL CLINICAL CONSIDERATIONS AND CONTEXT 8

2019 Belgian Health Care Knowledge Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>